BCM
RPRX icon

Brasada Capital Management’s Royalty Pharma RPRX Stock Holding History

Brasada Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Buy
123,473
+1,974
+2% +$103K 1.24% 23
2026
Q1 		$5.75M Buy
+121,499
New +$5.32M 1.05% 35

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brasada Capital Management's RPRX Position: Q2 2026 in Review

Brasada Capital Management increased its Royalty Pharma (RPRX) stake by 1.6% in Q2 2026, buying an estimated $103K and bringing the position to 123,473 shares worth $6.92M. The position accounts for 1.24% of the portfolio, ranked #23.

Brasada Capital Management first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Brasada Capital Management held 123,473 shares of Royalty Pharma worth $6.92M as of Q2 2026.
  • Brasada Capital Management bought 1,974 Royalty Pharma shares in Q2 2026, an estimated $103K.
  • Royalty Pharma made up 1.24% of Brasada Capital Management's portfolio in Q2 2026, its #23 holding.
  • Brasada Capital Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Brasada Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.